Edition:
United Kingdom

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

229.11USD
9:00pm BST
Change (% chg)

$-5.93 (-2.52%)
Prev Close
$235.04
Open
$232.94
Day's High
$233.22
Day's Low
$227.46
Volume
854,346
Avg. Vol
758,941
52-wk High
$388.67
52-wk Low
$216.13

Latest Key Developments (Source: Significant Developments)

Biogen Says Paul Mckenzie Notified Co That He Will Step Down As Executive Vice President, Pharmaceutical Operations & Technology Of Company
Wednesday, 15 May 2019 

May 15 (Reuters) - Biogen Inc ::BIOGEN SAYS ON MAY 9 PAUL MCKENZIE NOTIFIED CO THAT HE WILL STEP DOWN AS EXECUTIVE VICE PRESIDENT, PHARMACEUTICAL OPERATIONS & TECHNOLOGY OF COMPANY.BIOGEN INC - PAUL MCKENZIE STEPPING DOWN TO TAKE A POSITION AS CHIEF OPERATING OFFICER OF A BIOPHARMACEUTICAL COMPANY.BIOGEN INC SAYS MCKENZIE WILL REMAIN AT COMPANY THROUGH MAY 29 - SEC FILING.  Full Article

Nightstar Therapeutics Shareholders Approve Scheme Of Arrangement For Acquisition By Biogen
Wednesday, 8 May 2019 

May 8 (Reuters) - Nightstar Therapeutics PLC ::NIGHTSTAR THERAPEUTICS PLC SHAREHOLDERS APPROVE SCHEME OF ARRANGEMENT FOR ACQUISITION BY BIOGEN AT GENERAL MEETING AND COURT MEETING HELD ON 8 MAY 2019.NIGHTSTAR THERAPEUTICS PLC - EXPECTS THAT SCHEME OF ARRANGEMENT FOR ACQUISITION BY BIOGEN WILL BECOME EFFECTIVE ON 7 JUNE 2019.  Full Article

Biogen Says Government Of Province Of Saskatchewan Will Grant Access To Spinraza To Patients With SMA
Monday, 22 Apr 2019 

April 22 (Reuters) - Biogen Inc ::BIOGEN CANADA - GOVERNMENT OF PROVINCE OF SASKATCHEWAN WILL GRANT ACCESS TO SPINRAZA TO PATIENTS WITH SMA.  Full Article

Biogen Continues To Advance Innovation In SMA With New Data In Adults And Infants To Be Presented At MDA Clinical And Scientific Conference
Friday, 12 Apr 2019 

April 12 (Reuters) - Biogen Inc ::BIOGEN CONTINUES TO ADVANCE INNOVATION IN SMA WITH NEW DATA IN ADULTS AND INFANTS TO BE PRESENTED AT MDA CLINICAL AND SCIENTIFIC CONFERENCE.BIOGEN INC - ADDITIONAL DATA SHOW THAT NEUROFILAMENT COULD BE A BIOMARKER FOR SMA.BIOGEN INC - INFANTS WITH PRE-SYMPTOMATIC SMA TREATED WITH SPINRAZA ACHIEVE MOTOR MILESTONES THAT ARE MORE CONSISTENT WITH NORMAL DEVELOPMENT.BIOGEN INC - DATA SHOW THAT NEUROFILAMENT MAY PREDICT IMPROVEMENT IN MOTOR FUNCTION AND DISEASE ACTIVITY.BIOGEN INC - IN CLINICAL TRIAL PROGRAM, SPINRAZA DEMONSTRATED A FAVORABLE BENEFIT-RISK PROFILE.  Full Article

Biogen Inc Authorized A Program To Repurchase Up To $5 Bln Of Co's Common Stock
Monday, 25 Mar 2019 

March 25 (Reuters) - Biogen Inc ::BIOGEN INC - AUTHORIZED A PROGRAM TO REPURCHASE UP TO $5.0 BILLION OF THE COMPANY’S COMMON STOCK.BIOGEN INC - NEW REPURCHASE PROGRAM IS IN ADDITION TO ABOUT $1.7 BILLION REMAINING UNDER CURRENT SHARE REPURCHASE PROGRAM.BIOGEN INC - 2019 SHARE REPURCHASE PROGRAM DOES NOT HAVE AN EXPIRATION DATE.BIOGEN INC - ALL SHARE REPURCHASES UNDER THE 2019 SHARE REPURCHASE PROGRAM WILL BE RETIRED.  Full Article

Biogen, Eisai scrap Alzheimer's drug trials
Thursday, 21 Mar 2019 

March 21 (Reuters) - Biogen Inc ::BIOGEN AND EISAI TO DISCONTINUE PHASE 3 ENGAGE AND EMERGE TRIALS OF ADUCANUMAB IN ALZHEIMER’S DISEASE.BIOGEN INC - INDEPENDENT DATA MONITORING COMMITTEE ADVISES ADUCANUMAB UNLIKELY TO MEET PRIMARY ENDPOINTS, LEADING TO DECISION TO DISCONTINUE TRIALS.BIOGEN INC - DECISION TO STOP TRIALS IS BASED ON RESULTS OF A FUTILITY ANALYSIS CONDUCTED BY AN INDEPENDENT DATA MONITORING COMMITTEE.BIOGEN - AS PART OF THIS DECISION, EVOLVE PHASE 2 SAFETY STUDY AND LONG-TERM EXTENSION OF PRIME PHASE1B STUDY OF ADUCANUMAB WILL ALSO BE DISCONTINUED.BIOGEN INC - RESULTS INDICATED TRIALS WERE UNLIKELY TO MEET PRIMARY ENDPOINT UPON COMPLETION.BIOGEN INC - INITIATION OF ADUCANUMAB PHASE 3 SECONDARY PREVENTION TRIAL WILL BE ASSESSED WHILE DATA FROM ENGAGE AND EMERGE ARE FURTHER EVALUATED.BIOGEN INC - RECOMMENDATION TO STOP STUDIES WAS NOT BASED ON SAFETY CONCERNS..BIOGEN INC - EVOLVE PHASE 2 SAFETY STUDY AND LONG-TERM EXTENSION OF PRIME PHASE1B STUDY OF ADUCANUMAB WILL ALSO BE DISCONTINUED.BIOGEN AND EISAI TO DISCONTINUE PHASE 3 ENGAGE AND EMERGE TRIALS OF ADUCANUMAB IN ALZHEIMER'S DISEASE.  Full Article

Biogen Enters Into an Agreement to Sell Its Large-Scale Biologics Manufacturing Site in Hillerod, Denmark to Fujifilm
Tuesday, 12 Mar 2019 

March 12 (Reuters) - Biogen Inc ::BIOGEN EXPECTS NEW MANUFACTURING FACILITY IN SOLOTHURN, SWITZERLAND TO BE OPERATIONAL BY END OF 2020.BIOGEN ENTERS INTO AN AGREEMENT TO SELL ITS LARGE-SCALE BIOLOGICS MANUFACTURING SITE IN HILLERØD, DENMARK TO FUJIFILM.BIOGEN WILL ENTER INTO MANUFACTURING SERVICES AGREEMENTSWITH FUJIFILM TO SUPPLY TYSABRI AND THIRD-PARTY PRODUCTS.BIOGEN EXPECTS NEW MANUFACTURING FACILITY IN SOLOTHURN, SWITZERLAND TO BE OPERATIONAL BY END OF 2020.BIOGEN- EXPECTS TO RECORD TOTAL AFTER-TAX LOSS IN Q1 2019 OF ABOUT $130 MILLION TO $150 MILLION, OR $0.66 TO $0.76 PER DILUTED SHARE, RELATED TO PROPOSED TRANSACTION.  Full Article

Syncona Says Nightstar To Be Acquired By Biogen
Monday, 4 Mar 2019 

March 4 (Reuters) - Syncona Ltd ::NIGHTSTAR AGREEMENT TO BE ACQUIRED BY BIOGEN.PROPOSED DEAL FOR $877 MILLION.SYNCONA'S HOLDING VALUED AT £254.6 MILLION.SALE OF NIGHTSTAR WILL GENERATE £254.6 MILLION OF PROCEEDS FOR SYNCONA AND IS EXPECTED TO COMPLETE IN Q2.  Full Article

Biogen Further Expands Presence In China With Spinraza
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Biogen Inc ::BIOGEN FURTHER EXPANDS PRESENCE IN CHINA WITH APPROVAL OF SPINRAZA® (NUSINERSEN), THE FIRST AND ONLY TREATMENT FOR SPINAL MUSCULAR ATROPHY.BIOGEN - SPINRAZA WAS APPROVED UNDER CHINA NATIONAL MEDICAL PRODUCTS ASSOCIATION PRIORITY REVIEW PROCESS EVALUATING THERAPIES WITH URGENT CLINICAL NEEDS.  Full Article

Us FDA Approves Ontruzant, Samsung Bioepis' First Oncology Medicine In The U.S.
Sunday, 20 Jan 2019 

Jan 20 (Reuters) - Samsung Bioepis Co: :US FDA APPROVES ONTRUZANT® (TRASTUZUMAB-DTTB), SAMSUNG BIOEPIS’ FIRST ONCOLOGY MEDICINE IN THE UNITED STATES.SAMSUNG BIOEPIS CO - ONTRUZANT WILL BE MARKETED AND DISTRIBUTED IN UNITED STATES BY MERCK, WHICH IS KNOWN AS MSD OUTSIDE OF US AND CANADA.  Full Article

Novartis CEO plans gene therapy price 'far lower' than $4 mln to $5 mln range

BOSTON, May 22 Novartis AG's top executive said on Wednesday it expects to price its gene therapy for spinal muscular atrophy “far lower” than the $4 million to $5 million figure the Swiss drugmaker has said it could be worth.